Search Clinical Trials
Sponsor Condition of Interest |
---|
TMS as a Treatment for Apathy in Alzheimer's Disease
Massachusetts General Hospital
Alzheimer Disease
Apathy in Dementia
This proposal will demonstrate that non-invasive brain stimulation is able to modulate
cortico-striatal circuits in neurodegenerative patients with apathy, and that doing so
results in circuit-specific increases in FC and DA availability. These circuit changes
will be accompanied by changes in specific... expand
This proposal will demonstrate that non-invasive brain stimulation is able to modulate cortico-striatal circuits in neurodegenerative patients with apathy, and that doing so results in circuit-specific increases in FC and DA availability. These circuit changes will be accompanied by changes in specific behavioral dimensions of apathy. This work will lead to larger studies which develop personalized, circuit-specific neuromodulation strategies for AD patients suffering from this intractable neuropsychiatric symptom. Type: Interventional Start Date: May 2024 |
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
HER2-positive Advanced Solid Tumor
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and
tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2. expand
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2. Type: Interventional Start Date: Jan 2022 |
Let's Know!2: Language-focused Intervention for Children at Risk of Comprehension Difficulties
MGH Institute of Health Professions
Language Disorders in Children
In the proposed project, the investigators will conduct a multisite randomized controlled
trial (RCT) to determine the efficacy of Let's Know!2, a small-group, language focused
comprehension intervention, on children's lower- and higher-level language skills and
comprehension skills in the short-... expand
In the proposed project, the investigators will conduct a multisite randomized controlled trial (RCT) to determine the efficacy of Let's Know!2, a small-group, language focused comprehension intervention, on children's lower- and higher-level language skills and comprehension skills in the short- and long-term (Specific Aims 1 and 2). The investigators will also explore whether intervention effects are moderated by dosage, initial language skill, developmental language disorder (DLD) status, word reading skill, nonverbal IQ, and family socioeconomic status (Specific Aim 3). Children who have low language skills and are thus at risk for reading comprehension difficulties will participate in the study. Children will be randomly assigned to receive Let's Know! in small groups at their respective schools or to a business-as-usual control condition. The investigators will measure children's language and comprehension skills at the beginning and end of Grade 1 as well as in Grade 2 and Grade 3. The investigators hypothesize that children who experience Let's Know! will end Grade 1 with higher language skills than children in the control condition and that this will translate into better listening and reading comprehension skills as these children matriculate through elementary school. Type: Interventional Start Date: Jan 2021 |
A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)
Aspa Therapeutics
Canavan Disease
The main objective of this trial is to evaluate the safety, tolerability, and
pharmacodynamic activity of BBP-812, an investigational AAV9-based gene therapy, in
pediatric participants with Canavan disease. expand
The main objective of this trial is to evaluate the safety, tolerability, and pharmacodynamic activity of BBP-812, an investigational AAV9-based gene therapy, in pediatric participants with Canavan disease. Type: Interventional Start Date: Sep 2021 |
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
A2 Biotherapeutics Inc.
Solid Tumor, Adult
Colorectal Cancer
Non Small Cell Lung Cancer
Pancreatic Cancer
CRC
Objective:
To collect information on how often a solid tumor cancer might lose the Human Leukocyte
Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an
eligible participant's own T cells for future use to make CAR T-Cell therapy for their
disease treatment.
Design:
This... expand
Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Design: This is a non-interventional, observational study to evaluate participants with solid tumors with a high risk of relapse for incurable disease. No interventional therapy will be administered on this study. Some of the information regarding the participant's tumor analysis may be beneficial to management of their disease. Participants that meet all criteria may be enrolled and leukapheresed (blood cells collected). The participant's cells will be processed and stored for potential manufacture of CAR T-cell therapy upon relapse of their cancer. Type: Observational Start Date: Oct 2021 |
Study of INBRX-109 in Conventional Chondrosarcoma
Inhibrx Biosciences, Inc
Conventional Chondrosarcoma
Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or
metastatic conventional chondrosarcoma patients. expand
Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients. Type: Interventional Start Date: Sep 2021 |
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
Massachusetts General Hospital
Gout
The TRUST study is a randomized, controlled multicenter study to evaluate the management
of gout by comparing two commonly used treatment strategies for gout (TTT vs TTASx) to
determine the most beneficial for a patient-centered gout outcomes, as well as relevant
cardiovascular-metabolic-renal endpoints. expand
The TRUST study is a randomized, controlled multicenter study to evaluate the management of gout by comparing two commonly used treatment strategies for gout (TTT vs TTASx) to determine the most beneficial for a patient-centered gout outcomes, as well as relevant cardiovascular-metabolic-renal endpoints. Type: Interventional Start Date: Feb 2024 |
SBRT + Atezolizumab + Bevacizumab in Resectable HCC
Massachusetts General Hospital
Hepatocellular Carcinoma
Resectable Hepatocellular Carcinoma
This study is evaluating the safety and tolerability of neoadjuvant stereotactic body
radiation therapy (SBRT) with atezolizumab and bevacizumab for treating resectable
hepatocellular carcinoma.
This study involves the following study interventions:
- Atezolizumab
- Bevacizumab... expand
This study is evaluating the safety and tolerability of neoadjuvant stereotactic body radiation therapy (SBRT) with atezolizumab and bevacizumab for treating resectable hepatocellular carcinoma. This study involves the following study interventions: - Atezolizumab - Bevacizumab - Stereotactic Beam Radiation Therapy (SBRT) - Surgery Type: Interventional Start Date: Jun 2021 |
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma...
C4 Therapeutics, Inc.
Multiple Myeloma
Lymphoma, Non-Hodgkin's
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics,
pharmacodynamics, and antitumor activity of oral cemsidomide (also known as CFT7455)
administered at different dosages in subjects with Relapsed/Refractory (r/r)
Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma... expand
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of oral cemsidomide (also known as CFT7455) administered at different dosages in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). Cemsidomide may be administered as a single agent and, in MM only, in combination with oral dexamethasone. Type: Interventional Start Date: Apr 2021 |
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
United Therapeutics
Idiopathic Pulmonary Fibrosis
Interstitial Lung Disease
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against
placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52. expand
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52. Type: Interventional Start Date: Jun 2021 |
A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With...
Takeda
Solid Neoplasms
The main aim of this study is to check if people with advanced solid tumors have side
effects from dazostinag, and to check how much dazostinag they can receive without
getting significant side effects from it when given alone and in combination with
pembrolizumab. The study will be conducted in two... expand
The main aim of this study is to check if people with advanced solid tumors have side effects from dazostinag, and to check how much dazostinag they can receive without getting significant side effects from it when given alone and in combination with pembrolizumab. The study will be conducted in two phases including a dose escalation phase and a dose expansion phase. In the dose escalation phase, escalating doses of dazostinag are being tested alone and in combination with pembrolizumab to treat participants who have advanced or metastatic solid tumors. In the dose expansion phase, dazostinag will be studied with pembrolizumab with or without chemotherapy in participants with untreated metastatic or recurrent, unresectable squamous cell carcinoma of head and neck (SCCHN) and in combination with pembrolizumab in third-line or later recurrent locally advanced or metastatic microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and third-line recurrent locally advanced or metastatic microsatellite stable/mismatch repair proficient (MSS/pMMR) colorectal cancer (CRC). Type: Interventional Start Date: Jul 2020 |
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Alliance for Clinical Trials in Oncology
CDK Gene Mutation
Metastatic Malignant Neoplasm in the Brain
Metastatic Malignant Solid Neoplasm
NTRK Family Gene Mutation
PI3K Gene Mutation
This phase II trial studies how well genetic testing works in guiding treatment for
patients with solid tumors that have spread to the brain. Several genes have been found
to be altered or mutated in brain metastases such as NTRK, ROS1, CDK, PI3K, or KRAS G12C.
Medications that target these genes... expand
This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK, PI3K, or KRAS G12C. Medications that target these genes such as abemaciclib, paxalisib, entrectinib and adagrasib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genetic testing may help doctors tailor treatment for each mutation. Type: Interventional Start Date: Aug 2019 |
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL)...
Memorial Sloan Kettering Cancer Center
Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Leukemia (SLL)
The purpose of this study is to determine the rate of minimum residual disease (MRD)
negative response (i.e. the rate of no evidence of disease) of the study drugs,
zanubrutinib, obinutuzumab, and venetoclax, given in combination as a treatment for CLL
and/or SLL. expand
The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of the study drugs, zanubrutinib, obinutuzumab, and venetoclax, given in combination as a treatment for CLL and/or SLL. Type: Interventional Start Date: Feb 2019 |
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
National Cancer Institute (NCI)
Autoimmune Disease
Crohn Disease
Dermatomyositis
Hematopoietic and Lymphoid Cell Neoplasm
Inflammatory Bowel Disease
This phase Ib trial studies the side effects of nivolumab and to see how well it works in
treating patients with autoimmune disorders and cancer that has spread to other places in
the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as
nivolumab, may help the body's... expand
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Type: Interventional Start Date: Jul 2019 |
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Celgene
Neoplasms
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for
all pediatric and adult participants exposed to Gene-modified (GM) T cell therapy
participating in a previous Celgene sponsored or Celgene alliance partner sponsored
study.
Participants who received at least... expand
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one GM T cell infusion will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol. Type: Interventional Start Date: Jun 2018 |
Study of REM-422 in Patients With AML or Higher Risk MDS
Remix Therapeutics
Myelodysplastic Syndromes
Higher Risk Myelodysplastic Syndromes
Acute Myeloid Leukemia
Acute Myeloid Leukemia Refractory
The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB
mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML expand
The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML Type: Interventional Start Date: Apr 2024 |
Comprehensive HHT Outcomes Registry of the United States (CHORUS)
Cure HHT
Hereditary Hemorrhagic Telangiectasia
Arteriovenous Malformations
Telangiectasia
Epistaxis
GastroIntestinal Bleeding
The Comprehensive HHT Outcomes Registry of the United States (CHORUS) is an observational
registry of patients diagnosed with Hereditary Hemorrhagic Telangiectasia (HHT). The
purpose of this study is to better understand HHT, the symptoms and complications it
causes, and the impact the disease has... expand
The Comprehensive HHT Outcomes Registry of the United States (CHORUS) is an observational registry of patients diagnosed with Hereditary Hemorrhagic Telangiectasia (HHT). The purpose of this study is to better understand HHT, the symptoms and complications it causes, and the impact the disease has on people's lives. The investigators will collect long-term information about the participant, allowing us to understand how the disease changes over time, and what factors can influence those changes. Ultimately, this should help improve treatments for the disease. Another important goal of the study is to provide a way to contact people to participate in future clinical trials and other research. The registry will be a centralized resource for recruitment for clinical trials. People in the registry will not be obligated to join any of these additional studies, but if interested, can agree to be contacted if they may be eligible for a study. Participants will: - Be asked to provide permission to collect information from their medical records, including things like demographic information, diagnosis information, family history, test results, treatment information, symptoms, complications, lifestyle and other relevant medical information. - Be asked study-related questions by phone or at a clinic visit. - Be asked study-related questions every year after enrollment for up to 10 years or until the study ends. A member of the study team will communicate with participants by phone or at clinic visits to collect information regarding any changes to their health over the previous year/s including new test results, treatment information, symptoms, and complications from HHT. Type: Observational [Patient Registry] Start Date: Nov 2023 |
Safety and Effectiveness of Pulmonary Vein isOLation And posterioR Wall Ablation wIth pulSed Field Energy...
Massachusetts General Hospital
Atrial Fibrillation
The primary objective of this clinical investigation is to demonstrate the safety and
12-month effectiveness of pulmonary vein isolation (PVI) and posterior LA wall isolation
in the treatment of subjects with symptomatic paroxysmal and persistent atrial
fibrillation using the pulsed field ablation... expand
The primary objective of this clinical investigation is to demonstrate the safety and 12-month effectiveness of pulmonary vein isolation (PVI) and posterior LA wall isolation in the treatment of subjects with symptomatic paroxysmal and persistent atrial fibrillation using the pulsed field ablation with the VARIPULSEā¢ catheter and the TRUPULSEā¢ generator. Type: Interventional Start Date: Dec 2023 |
The Molecular Basis of Inherited Reproductive Disorders
Stephanie B. Seminara, MD
Hypogonadotropic Hypogonadism
Reproductive Disorder
Kallmann Syndrome
Delayed Puberty
The goal of this study is to learn more about the genes that control puberty and
reproduction in humans. expand
The goal of this study is to learn more about the genes that control puberty and reproduction in humans. Type: Observational Start Date: Jan 2021 |
Safety, Tolerability and Efficacy of AntiBKV as Treatment of BKV Infection in Kidney Transplant Recipients
Memo Therapeutics AG
BK Viremia; BKV DNAemia
The purpose of this study is to evaluate the safety, tolerability, and efficacy of
AntiBKV in reducing BKV DNAemia and progression to biopsy-confirmed BKVAN in kidney
transplant recipients. This study has an operationally seamless phase II/III design. The
phase II part will evaluate the safety of... expand
The purpose of this study is to evaluate the safety, tolerability, and efficacy of AntiBKV in reducing BKV DNAemia and progression to biopsy-confirmed BKVAN in kidney transplant recipients. This study has an operationally seamless phase II/III design. The phase II part will evaluate the safety of AntiBKV in kidney transplant recipients and establish antiviral proof of concept. The phase II part includes a dose-comparison part to generate additional PK and PD data of AntiBKV. The phase III part will assess the efficacy of AntiBKV in kidney transplant recipients. For both the phase II and phase III parts, participants will be randomized to receive either four doses of AntiBKV or four doses of placebo (every four weeks). In phase II, 60 participants will be first randomized (1:1) to receive either four doses of 1,000 mg of AntiBKV or placebo. In an additional dose-comparison extension, another 30 participants will be enrolled and randomized (1:1:1) to receive either four doses of 1,000 mg AntiBKV, four doses of 500 mg AntiBKV, or placebo. Based on a Day 141 analysis after phase II the sample size for the phase III part of the trial will be defined. Both the phase II and phase III parts will follow identical study assessments and schedules for participants. Eligible participants will receive an intravenous infusion of the investigational medicinal product (IMP) that will be administered four times at a four-week interval. For the first ten participants enrolled in the study, the infusion time will be at least 60 minutes. Provided there are no safety concerns observed with the first ten participants the duration of subsequent infusions will be at least 30 minutes. After administration of the final dose, participants will return as out participants for periodic safety, BKV DNAemia, and PK follow-up assessments until the end of the trial visits, 26 weeks post last IMP application. Regular kidney biopsies will be performed at baseline (prior to infusion) and on Day 141 (8 weeks after full dosing). An additional biopsy will be taken on Day 267 (optional) and if clinically indicated. Type: Interventional Start Date: Apr 2023 |
Blood Pressure Variability and Ischemic Stroke Outcome
Yale University
Acute Ischemic Stroke
Blood Pressure Variability
The goal of this observational study is to evaluate the role of blood pressure (BPV)
variability in patients suffering from acute ischemic stroke. The main questions it aims
to answer are:
1. To determine the association of BPV with functional/cognitive outcome after ischemic
stroke.... expand
The goal of this observational study is to evaluate the role of blood pressure (BPV) variability in patients suffering from acute ischemic stroke. The main questions it aims to answer are: 1. To determine the association of BPV with functional/cognitive outcome after ischemic stroke. 2. To determine a pathophysiologic mechanism of BPV's deleterious effect on functional outcome. 3. To evaluate potential treatment targets to pharmacologically reduce BPV after ischemic stroke. Type: Observational Start Date: Jul 2024 |
Intervention for Fatigue in HCT Recipients
Massachusetts General Hospital
Hematologic Cancer
Hematologic Malignancy
The purpose of this study is to assess whether a cognitive-behavioral therapy (CBT) for
fatigue intervention is acceptable, feasible, and effective at managing fatigue and
improving quality of life for patients following hematopoietic stem cell transplant
(HCT). expand
The purpose of this study is to assess whether a cognitive-behavioral therapy (CBT) for fatigue intervention is acceptable, feasible, and effective at managing fatigue and improving quality of life for patients following hematopoietic stem cell transplant (HCT). Type: Interventional Start Date: Nov 2023 |
Home-based Transcranial Direct Current Stimulation (tDCS) for Treatment of Attention-deficit/Hyperactivity...
Massachusetts General Hospital
Attention Deficit Disorder
Attention Deficit Disorder With Hyperactivity
The investigators are investigating whether home-based tDCS over the course of four weeks
can improve ADHD symptom severity and improve dysexecutive functioning (cognitive
control). Further, the investigators are investigating whether there is a dose-dependent
response to tDCS. expand
The investigators are investigating whether home-based tDCS over the course of four weeks can improve ADHD symptom severity and improve dysexecutive functioning (cognitive control). Further, the investigators are investigating whether there is a dose-dependent response to tDCS. Type: Interventional Start Date: Jul 2022 |
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic...
Regor Pharmaceuticals Inc.
Breast Cancer
This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety,
tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of RGT-419B
administered orally as monotherapy OR in combination with Hormonal Therapy in subjects
with HR+, HER2- locally advanced and unresectable... expand
This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of RGT-419B administered orally as monotherapy OR in combination with Hormonal Therapy in subjects with HR+, HER2- locally advanced and unresectable (Stage III) or metastatic (Stage IV) breast cancer whose disease has progressed during prior therapy with an approved CDK4/6i plus hormonal therapy. Type: Interventional Start Date: Mar 2022 |
PARADIGM: Amplatzer Valvular Plug for PVL Closure
Abbott Medical Devices
Paravalvular Aortic Regurgitation
The Paradigm study is a prospective, multicenter, single arm study to demonstrate the
safety and effectiveness of the Amplatzer Valvular Plug III (AVP III) as a treatment for
clinically significant PVLs following surgical implant of a mechanical or biological
heart valve implanted in the aortic or... expand
The Paradigm study is a prospective, multicenter, single arm study to demonstrate the safety and effectiveness of the Amplatzer Valvular Plug III (AVP III) as a treatment for clinically significant PVLs following surgical implant of a mechanical or biological heart valve implanted in the aortic or mitral position. Type: Interventional Start Date: Dec 2020 |
- Previous
- Next